Search
for

    Did you mean 11β-Hydroxysteroid Dehydrogenase Type 1?
    Glossary11β-Hydroxysteroid Dehydrogenase Type 1

    enzyme converting inactive cortisone to active cortisol

    11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) is an enzyme that converts inactive cortisone into active cortisol, a hormone involved in stress response, metabolism, and immune function. This enzyme is found in various tissues, including the liver and adipose tissue, and plays a role in conditions like obesity, diabetes, and potentially hair loss due to its influence on local cortisol levels.

    Related Terms

    Learn

    4 / 4 results

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Dutasteride

      Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity

      learn Metformin

      diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community ghk-cu is potent 5-ar inhibitor?

      in Product  9 upvotes 10 months ago
      GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

      community Finasteride gains continue well into year 5

      in Chat  118 upvotes 7 months ago
      Finasteride can continue to improve hair loss for up to 10 years, with the best results seen when started early. Combining treatments like minoxidil, dermarolling, or RU58841 may enhance effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 4 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.